{"id":"NCT04556656","sponsor":"Prilenia","briefTitle":"PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-16","primaryCompletion":"2023-03-14","completion":"2024-03-21","firstPosted":"2020-09-21","resultsPosted":"2025-03-12","lastUpdate":"2025-03-12"},"enrollment":499,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Huntington Disease"],"interventions":[{"type":"DRUG","name":"Pridopidine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pridopidine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).","primaryOutcome":{"measure":"Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)","timeFrame":"From baseline to Week 65","effectByArm":[{"arm":"Pridopidine","deltaMin":-1.18,"sd":0.119},{"arm":"Placebo","deltaMin":-0.95,"sd":0.119}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1670"}]},"eligibility":{"minAge":"25 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":58,"countries":["United States","Austria","Canada","Czechia","France","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":["40913168"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":250},"commonTop":["COVID-19","Fall","Diarrhea","Headache","Depression"]}}